Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Short term Debt (2016 - 2025)

Haemonetics has reported Short term Debt over the past 16 years, most recently at $304.7 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 5904.85% year-over-year to $304.7 million; the TTM value through Dec 2025 reached $304.7 million, up 5904.85%, while the annual FY2025 figure was $303.6 million, 2867.62% up from the prior year.
  • Short term Debt for Q4 2025 was $304.7 million at Haemonetics, roughly flat from $304.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $304.7 million in Q4 2025 and troughed at $5.1 million in Q4 2024.
  • A 5-year average of $92.3 million and a median of $15.4 million in 2021 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: crashed 94.5% in 2023 and later soared 5904.85% in 2025.
  • Year by year, Short term Debt stood at $82.7 million in 2021, then plummeted by 87.97% to $9.9 million in 2022, then soared by 38.06% to $13.7 million in 2023, then tumbled by 63.05% to $5.1 million in 2024, then soared by 5904.85% to $304.7 million in 2025.
  • Business Quant data shows Short term Debt for HAE at $304.7 million in Q4 2025, $304.3 million in Q3 2025, and $303.9 million in Q2 2025.